Immune Checkpoints in Solid Organ Transplantation
Allogenic graft acceptance is only achieved by life-long immunosuppression, which comes at the cost of significant toxicity. Clinicians face the challenge of adapting the patients’ treatments over long periods to lower the risks associated with these toxicities, permanently leveraging the risk of ex...
Main Authors: | Arnaud Del Bello, Emmanuel Treiner |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-10-01
|
Series: | Biology |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-7737/12/10/1358 |
Similar Items
-
Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
by: Jingyu Jiang, et al.
Published: (2023-02-01) -
Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies
by: Stephanie Ji, et al.
Published: (2023-10-01) -
Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance system
by: Xiangli Cui, et al.
Published: (2023-03-01) -
Use of immune checkpoint inhibition and conventional chemotherapy for multiple, concurrent malignancies post-lung transplantation: A case report
by: John P. Claiborne, et al.
Published: (2022-06-01) -
Editorial: Regulatory immune cells in organ transplantation
by: Hongxuan Ma, et al.
Published: (2024-02-01)